Repligen (RGEN) Research & Development (2010 - 2026)

Repligen (RGEN) has reported Research & Development for 17 consecutive years, with $14.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 3.2% year-over-year to $14.4 million in Q2 2026; TTM through Jun 2026 was $56.2 million, a 18.32% increase from a year earlier, with the FY2025 full-year figure at $54.2 million, up 25.41% from the prior year.
• Research & Development was $14.4 million for Q2 2026 at Repligen, roughly flat from $14.5 million in the prior quarter.
• Over five years, Research & Development peaked at $14.5 million in Q1 2026 and troughed at $9.7 million in Q2 2023.
• A 5-year average of $11.8 million and a median of $11.5 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 59.68% in 2022 and declined 8.2% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $11.1 million in 2022, then slipped by 7.45% to $10.3 million in 2023, then rose by 13.53% to $11.7 million in 2024, then grew by 12.36% to $13.1 million in 2025, then rose by 9.89% to $14.4 million in 2026.
• The last three Research & Development figures came in at $14.4 million (Q2 2026), $14.5 million (Q1 2026), and $13.1 million (Q4 2025), per Business Quant data.